Novartis AG - Guide to Insomnia

Diversified healthcare giant Novartis (NYSE:NVS) reported impressive 2011 results in January 2012. These strong trends are not projected to carry...

Celgene (NASDAQ: CELG) was downgraded by Argus from a "buy" rating to a "hold" rating in a research note issued on Friday.. . Separately, analysts...

Investment analysts at Barclays Capital (NYSE: BCS) boosted their price target on shares of Celgene (NASDAQ: CELG) from $77.00 to $83.00 in a note...

Celgene (NASDAQ: CELG)'s stock had its "neutral" rating reaffirmed by research analysts at Goldman Sachs (NYSE: GS) in a report issued on Friday...

Celgene (NASDAQ: CELG)'s stock had its "outperform" rating reiterated by Zacks Investment Research in a research note issued to investors on...

Taking a Framework Approach to Securing Electronic Health Records (EHRs)Prepare Now for a Rational and Sustainable Pathway to New Healthcare...

A unit of Novartis AG (NOVN), the Swiss drugmaker, won a judge's preliminary approval of a $99 million settlement in a lawsuit brought by sales...

Swiss drug maker Novartis AG reported a 47 percent drop in its fourth-quarter net profit Wednesday, citing a slate of exceptional costs from the ...

A U.S. division of Swiss drugmaker Novartis AG will pay $99 million to settle a class-action lawsuit about overtime pay for U.S. sales ...

Novartis expects 2012 sales to be in line with 2011. Fourth quarter sales rose 5% while core operating income grew 17% in constant currencies (cc)...

Topic: Novartis AG